Working…
ClinicalTrials.gov

Key Record Dates

ClinicalTrials.gov Identifier: NCT03835819
Brief Title: A Phase 2 Study of Mirvetuximab Soravtansine (IMGN853) and Pembrolizumab in Endometrial Cancer (EC)

First Submitted : February 6, 2019
First Submitted that Met QC Criteria : February 7, 2019
First Posted : February 11, 2019

Last Update Submitted that Met QC Criteria : December 7, 2020
Last Update Posted : December 9, 2020